Alpine Immune Sciences Inc

Alpine Immune Sciences — Nivalis Therapeutics — Technical Presentation (November 2016)

16 slides from Alpine Immune Sciences's technical presentation, Nov 28, 2016

  1. Slide 1: Agenda

    Introduction Mike Carruthers, Chief Financial Officer Initial Remarks Jon Congleton, President and CEO Data Highlights David Rodman, M.D., Chief Medical Officer Joining for Q&A Jan Troha, Chief Operating Officer Steve Shoemaker, M.D., VP Medical/Clinical Sherif Gabriel, PhD, VP Scientific Search Age

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to

  3. Slide 3: Cavosonstat Added to Orkambi in F508del Homozygous Patients – SNO-6 Results

    Cavosonstat at doses up to 400mg bid was well tolerated with no unanticipated safety findings. Treatment did not result in improvement in lung function over the twelve week period of treatment in this patient population. Modest reduction in sweat chloride, consistent with CFTR modulation, was confir

  4. Slide 4: SNO-6 Trial Top Line Results

    SNO-6 Trial Top Line Results David M. Rodman, MD Chief Medical Officer

  5. Slide 5: SNO-6 Trial Design

    SNO-6 Trial Design Orkambi+ Placebo Orkambi+ cavosonstat 200mg bid Orkambi+ cavosonstat 400mg bid OrkambiN=46 N=44 N=48 Week -16+ -4 0 1 2 4 6 8 12 16 Visits Screening Washout Orkambi Baseline Efficacy

  6. Slide 6: Baseline Demographics (138 Patients Enrolled)

    Baseline Demographics (138 Patients Enrolled) Placebo (N=46) Cavosonstat 200 mg (N=44) Cavosonstat 400 mg (N=48) Males % 45.7% 65.9% 52.1% Age (mean, years) (range) 31.5 (19-56) 30.6 (19-52) 31.6 (18-56) Baseline FEV1 (mean, % predicted) (range) 59.9% (29.8-86.4) 59.4% (38.7-83.9) 62.4% (38.3-83.9)

  7. Slide 7: Safety and Disposition

    Safety and Disposition Steve to insert safety summary slide here Placebo (N=46) Cavosonstat 200 mg BID (N=44) Cavosonstat 400 mg BID (N=48) Number of Patients who Experienced Any Adverse Event 42 (91.3%) 40 (90.9%) 40 (83.3%) Number of Patients who Discontinued Treatment Due to Adverse Events 2 (4.3

  8. Slide 8: Primary and Key Secondary Outcomes at Week 12

    Primary and Key Secondary Outcomes at Week 12* Placebo (N=46) 200 mg BID (N=44) 400 mg BID (N=48) Pooled Active (N=92) Absolute Change in FEV1 (% predicted) (Within group p-value) 0.97 (0.36) 0.39 (0.72) 0.35 (0.73) 0.37 (0.62) Relative Change in FEV1 (% predicted) (Within group p-value) 1.87 (0.31)

  9. Slide 9: FEV1 (Absolute % Predicted) Change from Baseline

    FEV1 (Absolute % Predicted) Change from Baseline -4 -3 -2 -1 0 1 2 3 4 0 4 8 12 16 Change from Baseline ± SEM (%) Study Visit (week) Placebo 200mg bid 400mg bid

  10. Slide 10: Sweat Chloride Change from Baseline

    Sweat Chloride Change from Baseline -6 -5 -4 -3 -2 -1 0 1 2 3 0 4 8 12 Change from Baseline ± SEM ( mmol /L) Study Visit (week) P<0.02 P<0.01 Cavosonstat 200mg bid Cavosonstat 400mg bid Placebo

  11. Slide 11: CFQ-R Respiratory Domain Change from Baseline

    CFQ-R Respiratory Domain Change from Baseline* Placebo Cavosonstat 200mg bid Cavosonstat 400mg bid * Arithmetic Means -10 -8 -6 -4 -2 0 2 4 6 8 0 4 8 12 16 Change from baseline ± CI Study Visit (week)

  12. Slide 12: Change in BMI and Body Weight

    Change in BMI and Body Weight P=0.39 P=0.09 P=0.08 *P=0.02 -0.4 -0.3 -0.2 -0.1 0 0.1 0.2 0.3 0.4 Placebo 200 mg 400 mg Pooled Actives Change from Baseline ± CI BMI Change from Baseline at Week 12 15.2% 4.3% 36.4% 27.3% 45.8% 25.0% 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% ? 1 kg ? 1.5 kg Weight Chan

  13. Slide 13: Summary of SNO-6 Trial

    Cavosonstat at doses up to 400mg bid was well tolerated with no unanticipated safety findings. Treatment did not result in improvement in lung function over the twelve week period of treatment in this patient population. Modest reduction in sweat chloride, consistent with CFTR modulation, was confir

  14. Slide 14: Forward Plans

    We do not envision moving forward with cavosonstat for treatment of CF-related lung disease in F508del homozygous patients. We await results of the SNO-7 trial in Kalydeco-treated patients heterozygous for F508del and a CFTR gating mutation. The observation of improved weight and BMI in an adult CF

  15. Slide 15: Forward Plans

    Forward Plans * We do not envision moving forward with cavosonstat for treatment of CF-related lung disease in F508del homozygous patients. * We await results of the SNO-7 trial in Kalydeco-treated patients heterozygous for F508del and a CFTR gating mutation. ¢ The observation of improved weight and

  16. Slide 16: Q&A

    Q&A

Nivalis Therapeutics — Technical Presentation (November 2016) on 6ix